Pre-Clinical
Pioneering
Preclinical Studies
with Unparalleled
Precision.
Traditional drug discovery efforts have often relied on simplified animal models that have poor translational validity, limiting our understanding of the complex interactions within the human body. By developing dynamic 3D tissue and organ models, we are determined to offer a holistic view of human biology.
Xellar’s Preclinical Development Platform enables the creation of tissue/organ chip disease models, built upon our proprietary high throughput barrier-free 3D organ chip technology. Our close-loop disease model platform allows for the study of disease progression, drug responses, and the evaluation of therapeutic interventions in a more accurate and predictive context.
By utilizing our expertise in surface modification and extracellular matrix (ECM) hydrogel formulation, we create organ-on-chip models that mimic the three-dimensional architecture, cellular composition, and mechanical properties of the cellular microenviroment of human tissues. This unique capability enables us to study diseases in a physiologically relevant microenvironment identify new therapeutic targets and assess the efficacy and safety of potential drugs with higher precision.
Our platform also includes advanced drug testing models, such as pharmacokinetics/pharmacodynamics (PK/PD) models, toxicity assessment models, and drug efficacy evaluation models. These models leverage various cell sourcing options, including cell lines, primary cells, organoids, and induced pluripotent stem cells (iPSCs), to replicate specific disease conditions and evaluate therapeutic interventions in a high throughput manner that is amenable for lab automation.
We empower researchers and pharmaceutical companies to advance their drug discovery efforts with unparalleled precision and relevance. By integrating expertise in biology, engineering, and computational analysis, we accelerate the identification of potential drug candidates and enhance the success rates of clinical trials.
